Tyra Biosciences, Inc. (TYRA): Capital Expenditures
$141.0K
Year ended 2025-12-31
$250.0K
Trailing 12 months to 2026-06-30
-36.8%
3-year compound annual growth
-14.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $141.0K | -78.8% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $664.0K | -13.8% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $770.0K | +37.7% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $559.0K | -15.4% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $661.0K | +111.9% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $312.0K | n/a | 2022-03-03, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $141.0K | -78.8% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $12.90M | -28.1% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $835.0K | n/a |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $171.0K | -88.4% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $11.0K | n/a |
| Annexon, Inc. (ANNX) | 2025-12-31 | $137.0K | +813.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $3.37M | n/m |
| Neurogene Inc. (NGNE) | 2025-12-31 | $1.18M | +46.4% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $231.0K | -55.1% |
Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗